[go: up one dir, main page]

MA28323A1 - Ameliorations concernant la vaccination - Google Patents

Ameliorations concernant la vaccination

Info

Publication number
MA28323A1
MA28323A1 MA28896A MA28896A MA28323A1 MA 28323 A1 MA28323 A1 MA 28323A1 MA 28896 A MA28896 A MA 28896A MA 28896 A MA28896 A MA 28896A MA 28323 A1 MA28323 A1 MA 28323A1
Authority
MA
Morocco
Prior art keywords
immunization
adjuvant systems
improvements relating
derivatives
nucleic acid
Prior art date
Application number
MA28896A
Other languages
English (en)
Inventor
Gary Peter Bembridge
Jennifer L Craigen
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28323A1 publication Critical patent/MA28323A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des vaccins dont l'acide nucléique est amélioré, des systèmes d'adjuvants, et des procédés pour l'élaboration de tels vaccins et systèmes d'adjuvants. Plus particulièrement, les vaccins à l'acide nucléique et les systèmes d'adjuvants de l'invention comprennent une combinaison d'une séquence de nucléotides codant le GM-CSF, ou certains de ses dérivés, et des agonistes des TLR (toll-like receptor), ou certains de leurs dérivés.
MA28896A 2003-09-15 2006-03-27 Ameliorations concernant la vaccination MA28323A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0321615.7A GB0321615D0 (en) 2003-09-15 2003-09-15 Improvements in vaccination

Publications (1)

Publication Number Publication Date
MA28323A1 true MA28323A1 (fr) 2006-12-01

Family

ID=29227139

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28896A MA28323A1 (fr) 2003-09-15 2006-03-27 Ameliorations concernant la vaccination

Country Status (19)

Country Link
US (1) US20080145375A1 (fr)
EP (1) EP1682175A2 (fr)
JP (1) JP2007505827A (fr)
KR (1) KR20070029111A (fr)
CN (1) CN1878567A (fr)
AU (1) AU2004271726A1 (fr)
BR (1) BRPI0414381A (fr)
CA (1) CA2538197A1 (fr)
GB (1) GB0321615D0 (fr)
IL (1) IL174131A0 (fr)
IS (1) IS8363A (fr)
MA (1) MA28323A1 (fr)
MX (1) MXPA06002969A (fr)
NO (1) NO20061242L (fr)
NZ (1) NZ545948A (fr)
RU (1) RU2370537C2 (fr)
SG (1) SG145767A1 (fr)
WO (1) WO2005025614A2 (fr)
ZA (1) ZA200602156B (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU2004266641A1 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
NZ545412A (en) 2003-08-27 2008-12-24 Coley Pharm Group Inc Aryloxy and arylalkyleneoxy substituted imidazoquinolines
US20050054665A1 (en) 2003-09-05 2005-03-10 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
WO2005032484A2 (fr) 2003-10-03 2005-04-14 3M Innovative Properties Company Imidazoquinolines a substitution alcoxy
JP2007511527A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー オキシム置換イミダゾ環化合物
JP2007511535A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシルアミン置換イミダゾ環化合物
NZ547467A (en) 2003-11-25 2010-06-25 3M Innovative Properties Co Substituted imidazo ring system and methods
FR2863890B1 (fr) * 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
WO2005066170A1 (fr) 2003-12-29 2005-07-21 3M Innovative Properties Company Imidazoquinolines a substitution arylalcenyle et arylalkynyle
US20050239735A1 (en) * 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
JP2007517044A (ja) 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
CA2559863A1 (fr) 2004-03-24 2005-10-13 3M Innovative Properties Company Imidazopyridines, imidazoquinolines, et imidazonaphthyridines a substitution amide
EP1755668A2 (fr) 2004-05-07 2007-02-28 Hans-Gustaf Ljunggren Adjuvants
WO2005123080A2 (fr) 2004-06-15 2005-12-29 3M Innovative Properties Company Imidazoquinolines et imidazonaphthyridines substituees par un heterocyclyle contenant un azote
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006009826A1 (fr) 2004-06-18 2006-01-26 3M Innovative Properties Company Thiazoloquinolines et thiazolonaphtyridines substitues par aryloxy et arylalkyleneoxy
WO2006065280A2 (fr) 2004-06-18 2006-06-22 3M Innovative Properties Company Composes a noyau imidazo a substitutif d'isoxazole, de dihydroisoxazole et d'oxadiazole
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
CA2602590A1 (fr) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Composes cycliques 1-pyrazolo[3,4-c] substitues comme modulateurs de la biosynthese de cytokine destines au traitement d'infections virales et de maladies neoplastiques
CA2602683A1 (fr) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines et analogues associes
WO2007011777A2 (fr) 2005-07-18 2007-01-25 Novartis Ag Modele petit animal pour une replication hcv
CA2623764A1 (fr) * 2005-09-27 2007-04-05 Coley Pharmaceutical Gmbh Modulation de reponses immunitaires mediees par tlr, au moyen d'oligonucleotides d'adaptation
CA2523032A1 (fr) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccins pour la therapie du cancer
CN101365715B (zh) * 2005-10-07 2013-03-27 P·安杰莱蒂分子生物学研究所 基质金属蛋白酶11疫苗
ATE534415T1 (de) 2005-12-13 2011-12-15 Harvard College Gerüste zur zelltransplantation
KR101105511B1 (ko) 2006-02-28 2012-01-16 박사르트, 인크. 키메라 아데노바이러스 벡터
US8173657B2 (en) 2006-03-23 2012-05-08 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
JP5427027B2 (ja) * 2006-05-03 2014-02-26 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
WO2007130493A2 (fr) 2006-05-03 2007-11-15 Regents Of The University Of Colorado Combinaison adjuvante synergique d'anticorps agoniste cd40/interféron de type 1, conjugués contenant une telle combinaison et utilisation en tant qu'agent thérapeutique pour améliorer l'immunité cellulaire
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
WO2008009652A2 (fr) 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccins contre le paludisme
GB0617387D0 (en) * 2006-09-04 2006-10-11 Glaxo Group Ltd Synthetic gene
CN101675068A (zh) 2007-03-02 2010-03-17 葛兰素史密丝克莱恩生物有限公司 新的方法和组合物
DE102007044093A1 (de) * 2007-09-14 2009-03-19 Phenion Gmbh & Co. Kg Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Induktion antimikrobieller Peptide in epithelialen Deckgeweben
US9498493B2 (en) 2007-09-27 2016-11-22 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
WO2009059328A2 (fr) * 2007-11-02 2009-05-07 The Johns Hopkins University Vaccin l2 multicomposant pour la prévention d'une infection de papillomavirus humain
KR100900837B1 (ko) * 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
JP5690143B2 (ja) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 持続的細胞プログラミング装置
JP5190628B2 (ja) * 2008-03-31 2013-04-24 一般財団法人阪大微生物病研究会 混合免疫賦活剤を含む新規ワクチン
US8410258B2 (en) 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
BRPI0912768A2 (pt) * 2008-05-21 2016-05-17 Infectious Disease Res Inst vacinas de poliproteínas recombinante para o tratamento e diagnóstico de leishmaniose
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
US20100160368A1 (en) * 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US8501926B2 (en) * 2008-09-24 2013-08-06 The Johns Hopkins University Malaria vaccine
MX2011005915A (es) * 2008-12-03 2011-08-17 Proyecto Biomedicina Cima Sl Uso de modulinas solubles en fenol para el desarrollo de vacunas.
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
PE20110998A1 (es) 2008-12-09 2012-02-10 Coley Pharm Group Inc Oligonucleotidos inmunoestimuladores
NZ597182A (en) * 2009-05-22 2014-07-25 Genocea Biosciences Inc Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
CA2803282C (fr) 2009-07-06 2018-05-01 David E. Anderson Procedes pour preparer des vesicules et formulations produites a partir de ces procedes
EP2453747B1 (fr) 2009-07-13 2017-08-30 Medicis Pharmaceutical Corporation Formulations d'imiquimod à intensité de dosage plus faible et régimes posologiques courts pour traiter des verrues génitales et périanales
US20110077263A1 (en) * 2009-09-29 2011-03-31 University Of Southern California Methods and Compositions of Toll-Like Receptor (TLR) Agonists
CA2798074A1 (fr) * 2010-04-27 2011-11-03 The Johns Hopkins University Compositions immunogenes et methodes de traitement d'une neoplasie
BR112013000394B8 (pt) 2010-07-06 2022-01-18 Variation Biotechnologies Inc Composição imunogênica, uso da mesma e método para preparar a referida composição
PT2606047T (pt) * 2010-08-17 2017-04-07 3M Innovative Properties Co Composições, formulações e métodos de um composto lipidado modificador da resposta imunitária
WO2012040101A1 (fr) 2010-09-21 2012-03-29 University Of Miami Compositions et procédés destinés à induire la migration de cellules dendritiques et une réponse immunitaire
ES2773858T3 (es) 2010-10-06 2020-07-15 Harvard College Hidrogeles formadores de poros inyectables para terapias celulares basadas en materiales
EP2643014A4 (fr) 2010-11-24 2015-11-11 Genocea Biosciences Inc Vaccins contre le virus de type 2 de l'herpès simplex: compositions et procédés pour la stimulation d'une réponse immunitaire
FR2969657B1 (fr) 2010-12-22 2014-02-07 Fabre Pierre Dermo Cosmetique Nouvelle bacterie et extraits de ladite bacterie et leur utilisation en dermatologie
FR2969658B1 (fr) * 2010-12-22 2014-10-17 Fabre Pierre Dermo Cosmetique Nouvelle bacterie et extraits de ladite bacterie et leur utilisation therapeutique
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
WO2012113413A1 (fr) * 2011-02-21 2012-08-30 Curevac Gmbh Composition de vaccin comprenant des acides nucléiques immunostimulateurs complexés et des antigènes emballés avec des conjugués de polyéthylèneglycol/peptide à liaison disulfure
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
WO2013025972A1 (fr) * 2011-08-17 2013-02-21 Globeimmune, Inc. Compositions immunothérapeutiques de -muc1 de levure et leurs utilisations
WO2013043647A1 (fr) * 2011-09-19 2013-03-28 The Johns Hopkins University Immunothérapie anticancéreuse
AU2012321022B2 (en) 2011-10-06 2017-03-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
WO2013078299A1 (fr) 2011-11-23 2013-05-30 Genocea Biosciences, Inc. Vaccins à acide nucléique contre le virus d'herpès simplex de type 2 : compositions et procédés pour susciter une réponse immunitaire
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (fr) 2012-01-27 2015-11-04 Variation Biotechnologies Inc Procédés et compositions pour agents thérapeutiques
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
KR101501583B1 (ko) * 2013-03-29 2015-03-12 주식회사 차백신연구소 리포펩티드 및 폴리(ｉ:ｃ)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물
US20160058856A1 (en) * 2013-04-05 2016-03-03 Kyushu University, National University Corporation Anti-tumor dna vaccine
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
HUE043042T2 (hu) * 2013-11-01 2019-07-29 Pfizer Vektorok prosztatához kapcsolódó antigének expressziójára
WO2015092710A1 (fr) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Administration simultanée controlatérale de vaccins
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
WO2016123573A1 (fr) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Matériaux péritumoraux et intratumoraux pour traitement anticancéreux
EP3280464A4 (fr) 2015-04-10 2018-09-26 President and Fellows of Harvard College Dispositifs de piégeage de cellules immunitaires et leurs procédés de fabrication et d'utilisation
US10857228B2 (en) 2015-06-10 2020-12-08 The University Of Tokyo Adjuvant for vaccines, vaccine, and immunity induction method
CN105031646A (zh) * 2015-07-16 2015-11-11 一达国际生物科技(北京)有限公司 抗肿瘤疫苗佐剂、其制备方法和编码核酸以及抗肿瘤疫苗组合物
US10925950B2 (en) 2015-08-03 2021-02-23 University Of Washington Immunogenic compositions, antigen screening methods, and methods of generating immune responses
CN115531609A (zh) 2016-02-06 2022-12-30 哈佛学院校长同事会 重塑造血巢以重建免疫
CN115537372A (zh) 2016-07-13 2022-12-30 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
WO2018026884A1 (fr) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomatériaux pour moduler des réponses immunitaires
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
WO2020061129A1 (fr) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions et procédés de marquage et de modulation de cellules in vitro et in vivo
JP2022549270A (ja) 2019-09-23 2022-11-24 プレジデント アンド フェローズ オブ ハーバード カレッジ バイオマテリアルベースの無抗原ワクチンおよびその使用
EP4149527A4 (fr) * 2020-05-14 2024-07-10 Ascendo Biotechnology, Inc. Ciblage sélectif de l'interaction treml1/md2 par un petit peptide ou une petite protéine et son utilisation pour des adjuvants vaccinaux
CN114377122B (zh) * 2022-01-18 2023-04-07 四川大学 一种基于四面体框架核酸的复合佐剂、mRNA疫苗及其制备方法和用途
CN115819617A (zh) * 2022-08-19 2023-03-21 辽宁成大生物股份有限公司 一种水痘-带状疱疹病毒重组嵌合蛋白及其编码基因、重组质粒载体、转化体和疫苗

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US6005099A (en) 1993-11-17 1999-12-21 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
DE69534348T2 (de) 1994-01-21 2006-05-24 Powderject Vaccines, Inc., Madison Gasbetätigtes Element zum Austragen von Genmaterial
DE69836206T2 (de) 1997-02-07 2007-08-23 Merck & Co., Inc. Synthetische hiv gag gene
ATE278419T1 (de) 1997-04-01 2004-10-15 Corixa Corp Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
WO1998050567A1 (fr) * 1997-05-02 1998-11-12 Abbott Laboratories Reactifs et procedes pour detecter les maladies de la prostate
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
PT1659179E (pt) 1998-02-05 2011-09-16 Glaxosmithkline Biolog Sa Derivados de antigénios associados a tumor da família mage e sequências de ácidos nucleicos codificando-os, utilizados para a preparação de proteínas de fusão e de composições para vacinação
KR20010041528A (ko) * 1998-03-02 2001-05-25 어플라이드 백신 테크놀로지스 코포레이션 면역 반응을 조절하는 방법 및 그 장치
IL138809A0 (en) 1998-04-07 2001-10-31 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and pharmaceutical compositions containing the same
ES2348708T3 (es) 1999-01-29 2010-12-13 Corixa Corporation Proteinas de fusion de her-2/neu.
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
GB0027088D0 (en) 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
AU7569501A (en) 2000-07-21 2002-02-05 Glaxo Group Ltd Codon-optimized papilloma virus sequences
EP1478371A4 (fr) * 2001-10-12 2007-11-07 Univ Iowa Res Found Methodes et produits permettant d'ameliorer des reponses immunitaires a l'aide de compose d'imidazoquinoline
GB0212046D0 (en) 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
CN100360558C (zh) 2002-06-11 2008-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物

Also Published As

Publication number Publication date
IS8363A (is) 2006-03-20
WO2005025614A3 (fr) 2005-10-06
SG145767A1 (en) 2008-09-29
ZA200602156B (en) 2007-07-25
NZ545948A (en) 2009-07-31
KR20070029111A (ko) 2007-03-13
US20080145375A1 (en) 2008-06-19
EP1682175A2 (fr) 2006-07-26
RU2006106848A (ru) 2007-10-27
MXPA06002969A (es) 2007-03-26
GB0321615D0 (en) 2003-10-15
NO20061242L (no) 2006-06-01
RU2370537C2 (ru) 2009-10-20
AU2004271726A1 (en) 2005-03-24
JP2007505827A (ja) 2007-03-15
IL174131A0 (en) 2006-08-01
WO2005025614A2 (fr) 2005-03-24
BRPI0414381A (pt) 2006-11-21
CA2538197A1 (fr) 2005-03-24
CN1878567A (zh) 2006-12-13

Similar Documents

Publication Publication Date Title
MA28323A1 (fr) Ameliorations concernant la vaccination
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
NL300899I2 (nl) Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit en Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie B01 eiwit
MXPA01003557A (es) Secuencias genomicas de neisseria y metodos para su uso.
BR9906927A (pt) Proteìnas de neisseria meningitidis
CY1109506T1 (el) ΛΟΙΜΟΓΟΝΟ cDNA ΕΝΟΣ ΕΓΚΕΚΡΙΜΕΝΟΥ ΣΤΕΛΕΧΟΥΣ ΕΜΒΟΛΙΟΥ ΤΟΥ ΙΟΥ ΤΗΣ ΙΛΑΡΑΣ. ΧΡΗΣΗ ΓΙΑ ΑΝΟΣΟΓΟΝΕΣ ΣΥΝΘΕΣΕΙΣ
CY1107390T1 (el) Εμβολιο εναντι αντιγονων απο βακτηριδια
MA30866B1 (fr) Vaccin
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
ATE406912T1 (de) Immunisierung gegen chlamydia tracheomatis
LU91734I2 (fr) Menveo - oligosaccharide méningococcique du group Y conjugué à la protéine CRM197 de Corynebacteriumdiphteriae.
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
DE60120621D1 (de) Lawsonia intracellularis Impfstoff
DE60226175D1 (de) Mycobakterieller impfstoff
ATE521621T1 (de) Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
CY1107845T1 (el) Γενετικα εμβολια με ανοσοενισχυτικο
ATE450545T1 (de) Impfstoff mit lawsonia intracellularis- untereinheit
EP1667634A4 (fr) Vaccin contre l'anthrax
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
ATE538808T1 (de) Kombinierte dns/protein impfstoffzusammensetzungen
DK1913957T3 (da) Genetiske adjuvant-vacciner
TH87147A (th) วัคซีนสำหรับการทำให้เกิดภูมิคุ้มกันที่ต้านเชื้อเฮลิโคแมคเตอร์